Comparison of Empagliflozin Versus Vildagliptin in Combination with Metformin in Individuals Diagnosed with Type II Diabetes Mellitus
Abstract
Objective: To compare the outcome of combination of vildagliptin with metformin empagliflozin with metformin in individuals diagnosed with type II diabetes mellitus Study design: Randomized controlled trial. Place and duration of study: Department of Medicine, AIMS, Muzaffarabad, AJK from 21 January, 2025 to 15 June, 2025. Methodology: Three hundred and twenty individuals, fulfilled the selection criteria, were included. Then individuals were randomly allocated in 02 groups. In group-A, individuals were prescribed once daily oral empagliflozin plus metformin at the dose of 10/1000 mg. In group-B, individuals were prescribed once daily oral vildagliptin plus metformin at the dose of 50/1000 mg. At baseline and after 12 weeks of follow-up, HbA1c, fasting blood glucose level and lipid profile were assessed. Data was analyzed in SPSS v.25.0, with P–value ≤ 0.05 as significant. Results: In this trial, we enrolled total 320 individuals and randomized them in two equal group. The mean age of individuals enrolled in Group-A was 56.16 ± 9.57 years as well as in Group-B was 57.86 ± 9.33 years. In Group-A, there were 94 (58.8%) men and 66 (41.3%) women. In Group-B, there were 79 (49.4%) men and 81 (50.6%) women. The median change in HBA1c level in Group-A that was 0.80 (IQR: 0.78) % and in Group-B was 1.00 (IQR: 0.80) %. The median change in HBA1 was more achieve in Group-B, however the difference was insignificant (p>0.05). In Group-A, the median change in fasting blood glucose level…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 320 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.